Results 31 to 40 of about 13,220 (219)

Identification of a Novel Ceftazidime-Avibactam-Resistant KPC-2 Variant, KPC-123, in Citrobacter koseri Following Ceftazidime-Avibactam Treatment

Frontiers in Microbiology, 2022
This study reported the identification of a novel ceftazidime-avibactam-resistant KPC-2 variant, KPC-123, in a Citrobacter koseri isolated from a patient in a Chinese hospital following ceftazidime-avibactam treatment of infection caused by OXA-232-producing Klebsiella pneumoniae.
Lin Wang, Weiyi Shen, Rong Zhang, Jiachang Cai   +3 more
openaire   +3 more sources

Resistance to ceftazidime–avibactam and underlying mechanisms

Journal of Global Antimicrobial Resistance, 2020
Ceftazidime-avibactam (CAZ-AVI) is a novel synthetic β-lactamase inhibitor combination. Although the combination has been available clinically for only a few years, cases of resistance to CAZ-AVI have already been reported.In the present review, we summarize the distribution of CAZ-AVI-resistant strains and the possible resistance mechanisms.There are ...
Yuhang Wang, Jin Wang, Rui Wang, Yun Cai
openaire   +3 more sources

Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-2016 [PDF]

, 2017
Background: Ceftazidime/avibactam combines an established oxyimino-cephalosporin with the first diazabicyclooctane β-lactamase inhibitor to enter clinical use.
Doumith, Michel, Hill, Robert, Hopkins, Katie L, Livermore, David M, Meunier, Danièle, Pike, Rachel, Staves, Peter, Woodford, Neil   +7 more
core   +1 more source

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa [PDF]

Antimicrobial Agents and Chemotherapy, 2018
Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI, and EUCAST as susceptible ...
Wright W. Nichols, Gregory G. Stone, Paul Newell, Helen Broadhurst, Angela Wardman, Merran MacPherson, Katrina Yates, Todd Riccobene, Ian A. Critchley, Shampa Das   +9 more
openaire   +2 more sources

Effect of β-lactamase inhibitors on in vitro activity of β-lactam antibiotics against Burkholderia cepacia complex species [PDF]

, 2016
Background: Bacteria belonging to the Burkholderia cepacia complex (Bcc) are an important cause of chronic respiratory tract infections in cystic fibrosis patients. Intrinsic resistance to a wide range of antimicrobial agents, including a variety of beta-
Coenye, Tom, Everaert, Annelien
core   +2 more sources

Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa

International Journal of Infectious Diseases, 2017
Objective: This study compared the activity of ceftolozane–tazobactam and ceftazidime–avibactam against 120 bacterial strains, including extended-spectrum beta-lactamase (ESBL) producers, carbapenem-resistant Enterobacteriaceae (CRE), and Pseudomonas ...
Adnan Alatoom, Hashim Elsayed, Karen Lawlor, Laila AbdelWareth, Rania El-Lababidi, Lysettee Cardona, Mohammad Mooty, Maria-Fernanda Bonilla, Ahmad Nusair, Imran Mirza   +9 more
doaj   +1 more source

Increased zinc levels facilitate phenotypic detection of ceftazidime-avibactam resistance in metallo-β-lactamase-producing Gram-negative bacteria

Frontiers in Microbiology, 2022
Ceftazidime-avibactam is one of the last resort antimicrobial agents for the treatment of carbapenem-resistant, Gram-negative bacteria. Metallo-β-lactamase-producing bacteria are considered to be ceftazidime-avibactam resistant. Here, we evaluated a semi-
Michaela Simon, Michaela Simon, Roman G. Gerlach, Yvonne Pfeifer, Niels Pfennigwerth, Sören G. Gatermann, Agnes Schröder, Agnes Schröder, Andreas Hiergeist, Axel Hamprecht, Axel Hamprecht, Axel Hamprecht, Axel Hamprecht, Tamara Rügamer, André Gessner, Jonathan Jantsch, Jonathan Jantsch   +16 more
doaj   +1 more source

A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring bla_KPC-14 Isolated in New York City

mSphere, 2020
Ceftazidime-avibactam is a potent antibiotic combination against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. Here, we describe a unique ceftazidime-avibactam-resistant and carbapenem-susceptible K.
Siqiang Niu, Kalyan D. Chavda, Jie Wei, Chunhong Zou, Steven H. Marshall, Puneet Dhawan, Deqiang Wang, Robert A. Bonomo, Barry N. Kreiswirth, Liang Chen   +9 more
doaj   +3 more sources

In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019

Brazilian Journal of Infectious Diseases, 2021
The Antimicrobial Testing Leadership and Surveillance (ATLAS) global surveillance program collected clinical isolates of Enterobacterales (n = 8416) and Pseudomonas aeruginosa (n = 2521) from 41 medical centers in 10 Latin American countries from 2017 to
James A. Karlowsky, Krystyna M. Kazmierczak, Maria Lavínea Novis de Figueiredo Valente, Elkin Lemos Luengas, Monique Baudrit, Alvaro Quintana, Paurus Irani, Gregory G. Stone, Daniel F. Sahm   +8 more
doaj   +1 more source

The Surgical Infection Society revised guidelines on the management of intra-abdominal infection [PDF]

, 2017
Background: Previous evidence-based guidelines on the management of intra-abdominal infection (IAI) were published by the Surgical Infection Society (SIS) in 1992, 2002, and 2010. At the time the most recent guideline was released, the plan was to update
Chang, Phillip K, Diaz, Jose J, Jr, Huston, Jared M, May, Addison K, Mazuski, John E, Mollen, Kevin P, Nadler, Evan P, O\u27Neill, Patrick J, Prince, Jose M, Rosengart, Matthew R, Sawyer, Robert G, Tessier, Jeffrey M   +11 more
core   +3 more sources